benthiocarb (Bolero)

06/01/2014 - "[BOLERO -- another remarkable step in treatment of breast cancer]."
11/01/2012 - "The two randomized trials (BOLERO-2 and TAMRAD) evaluating everolimus±endocrine therapy in a selected subgroup of HR-positive metastatic breast cancer patients have demonstrated a significant improvement in progression free survival for the combination compared to the endocrine therapy alone. "
07/01/2014 - "These preclinical data support the findings of the BOLERO 3 trial that shows that targeting of the PI3K/mTOR pathway in combination with trastuzumab is beneficial in trastuzumab-resistant breast cancer."
01/01/2014 - "The activity of everolimus was demonstrated in three phase III randomized placebo-controlled trials, RADIANT-3, RECORD 1 and BOLERO 2, in patients with pNETs, mRCC and breast carcinoma, respectively. "
04/01/2012 - "Based on these promising results, everolimus is currently under evaluation in a series of phase III Breast Cancer Trials of Oral Everolimus (BOLERO) trials of women with HER2-positive and estrogen receptor-positive breast cancer. "

01/01/2021 - "Training the basic steps of Bolero and stretching significantly improved balance in this sample of stroke patients."
01/01/2021 - "The study included a sample of 11 individuals diagnosed with stroke, who were assessed before and after training Bolero steps and stretching. "
01/01/2021 - "This study aimed to investigate the contribution of Bolero basic steps and stretching to the balance of stroke patients. "
01/01/2021 - "Effects of Bolero basic steps on balance and functional mobility in post-stroke hemiparesis: A pilot study."

03/01/2009 - "Mean values of the parameters generated by the BOLERO analysis for the tumor were K(trans) = 0.023 +/- 0.014 s(-1), tau(i) = 1.3 +/- 0.6 seconds, and v(e) = 0.51. "
01/01/2007 - "DCE MRI data analyzed by the BOLus Enhanced Relaxation Overview (BOLERO) method in conjunction with concurrent measurements of the arterial input function yielded a blood transfer rate constant (Ktrans) which measures perfusion/permeability, that was significantly higher in the core of the indolent tumor than in the core of the aggressive tumor. "
08/01/2004 - "The time-dependent 1H2O relaxation rate constant (R1 = 1/T1) in the tumor was modeled using the BOLus Enhanced Relaxation Overview (BOLERO) method in two modes regarding the equilibrium transcytolemmal water exchange system: 1) constraining it exclusively to the fast exchange limit (FXL) (the conventional assumption), and 2) allowing its transient departure from FXL and access to the fast exchange regime (FXR), thus designated FXL/FXR. "
03/01/2009 - "Dynamic contrast-enhanced MRI was performed on four Fischer rats bearing intracranial 9L gliomas, and the dynamic data were evaluated using the bolus-enhanced relaxation overview (BOLERO) model yielding maps of K(trans), v(e), and tau(i) values from the tumor. "
01/19/2016 - "Findings from a qualitative interview study embedded in the Cancer Research UK BOLERO trial (Bladder cancer: Open versus Lapararoscopic or RObotic cystectomy)."

09/01/1989 - "In this study we report that uptake of 45calcium(45Ca) by neonate rat brain synaptosomes was disrupted during benthiocarb poisoning. "
07/01/1989 - "Decreased activities of Mg2+ and Ca2+-ATPases suggests impairment in energy synthesis and utilization processes in developing CNS of rat during benthiocarb poisoning. "

01/01/2014 - "In the primary comparison (PFS analysis based on the local review of disease progression from BOLERO-2 with the data from the other studies), everolimus plus exemestane appeared to be more efficacious than both fulvestrant 250 mg (HR = 0.47; 95 % credible interval [CrI] 0.38-0.58) and 500 mg (HR = 0.59; 95 % CrI 0.45-0.77). "